Bmy stock forecast 2025 analysts’ earnings estimates show BMY

Analysts’ earnings estimates show BMY revenue potentially reaching $47B in 2025, with biopharma innovations acting as catalysts within an otherwise mature portfolio. Investors should also note Bristol Myers Squibb's current valuation metrics, including its Forward P/E ratio of 8.77. This expresses a discount compared to the average Forward P/E of 19.21 of its industry. Bristol Myers posted net income of $2.5 billion, or $1.20 per share, for the first quarter. That compares with a net loss of $11.9 billion, or a loss of $5.89 per share, for the year-earlier period. Sell-side forecasts for BMY in 2025 place forward P/E ratios around 8.9, implying undervaluation compared to industry averages, which could attract value-focused portfolios.